Literature DB >> 19693710

Mouse striatal dopamine nerve terminals express alpha4alpha5beta2 and two stoichiometric forms of alpha4beta2*-nicotinic acetylcholine receptors.

Sharon R Grady1, Outi Salminen, J Michael McIntosh, Michael J Marks, Allan C Collins.   

Abstract

Wild-type and alpha5 null mutant mice were used to identify nicotinic cholinergic receptors (nAChRs) that mediate alpha-conotoxin MII (alpha-CtxMII)-resistant dopamine (DA) release from striatal synaptosomes. Concentration-effect curves for ACh-stimulated release (20 s) were monophasic when wild-type synaptosomes were assayed but biphasic with synaptosomes from the alpha5 null mutant. Deleting the alpha5 gene also resulted in decreased maximal ACh-stimulated alpha-CtxMII-resistant DA release. When a shorter perfusion time (5 s) was used, biphasic curves were detected in both wild-type and alpha5 null mutants, indicative of high- and low-sensitivity (HS and LS) activity. In addition, DHbetaE-sensitive (HS) and DHbetaE-resistant (LS) components were found in both genotypes. These results indicate that alpha-CtxMII-resistant DA release is mediated by alpha4alpha5beta2, (alpha4)(2)(beta2)(3) (HS), and (alpha4)(3)(beta2)(2) (LS) nAChRs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19693710      PMCID: PMC4386732          DOI: 10.1007/s12031-009-9263-y

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  21 in total

1.  Nicotinic alpha5 subunit deletion locally reduces high-affinity agonist activation without altering nicotinic receptor numbers.

Authors:  Robert W B Brown; Allan C Collins; Jon M Lindstrom; Paul Whiteaker
Journal:  J Neurochem       Date:  2007-06-15       Impact factor: 5.372

2.  The subunit composition and pharmacology of alpha-Conotoxin MII-binding nicotinic acetylcholine receptors studied by a novel membrane-binding assay.

Authors:  Outi Salminen; Paul Whiteaker; Sharon R Grady; Allan C Collins; J Michael McIntosh; Michael J Marks
Journal:  Neuropharmacology       Date:  2005-04       Impact factor: 5.250

3.  Nicotinic-agonist stimulated (86)Rb(+) efflux and [(3)H]epibatidine binding of mice differing in beta2 genotype.

Authors:  M J Marks; J A Stitzel; S R Grady; M R Picciotto; J P Changeux; A C Collins
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

4.  The nicotinic acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in vivo.

Authors:  Ramiro Salas; Avi Orr-Urtreger; Ron S Broide; Arthur Beaudet; Richard Paylor; Mariella De Biasi
Journal:  Mol Pharmacol       Date:  2003-05       Impact factor: 4.436

5.  Partial deletion of the nicotinic cholinergic receptor alpha 4 or beta 2 subunit genes changes the acetylcholine sensitivity of receptor-mediated 86Rb+ efflux in cortex and thalamus and alters relative expression of alpha 4 and beta 2 subunits.

Authors:  Cecilia Gotti; Milena Moretti; Natalie M Meinerz; Francesco Clementi; Annalisa Gaimarri; Allan C Collins; Michael J Marks
Journal:  Mol Pharmacol       Date:  2008-03-12       Impact factor: 4.436

6.  alpha 5 Subunit alters desensitization, pharmacology, Ca++ permeability and Ca++ modulation of human neuronal alpha 3 nicotinic receptors.

Authors:  V Gerzanich; F Wang; A Kuryatov; J Lindstrom
Journal:  J Pharmacol Exp Ther       Date:  1998-07       Impact factor: 4.030

7.  Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice.

Authors:  Outi Salminen; Karen L Murphy; J Michael McIntosh; John Drago; Michael J Marks; Allan C Collins; Sharon R Grady
Journal:  Mol Pharmacol       Date:  2004-06       Impact factor: 4.436

8.  Rat nicotinic acetylcholine receptor alpha2beta2 channels: comparison of functional properties with alpha4beta2 channels in Xenopus oocytes.

Authors:  S S Khiroug; L Khiroug; J L Yakel
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

9.  Gene targeting demonstrates that alpha4 nicotinic acetylcholine receptor subunits contribute to expression of diverse [3H]epibatidine binding sites and components of biphasic 86Rb+ efflux with high and low sensitivity to stimulation by acetylcholine.

Authors:  Michael J Marks; Natalie M Meinerz; John Drago; Allan C Collins
Journal:  Neuropharmacology       Date:  2007-06-07       Impact factor: 5.250

10.  Pharmacology of alpha-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice.

Authors:  Outi Salminen; Jennifer A Drapeau; J Michael McIntosh; Allan C Collins; Michael J Marks; Sharon R Grady
Journal:  Mol Pharmacol       Date:  2007-03-06       Impact factor: 4.436

View more
  33 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  alpha4beta2 Nicotinic acetylcholine receptors, willing if able.

Authors:  Roger L Papke
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

3.  Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice.

Authors:  K J Jackson; M J Marks; R E Vann; X Chen; T F Gamage; J A Warner; M I Damaj
Journal:  J Pharmacol Exp Ther       Date:  2010-04-16       Impact factor: 4.030

4.  The nicotinic acetylcholine receptor alpha5 subunit plays a key role in attention circuitry and accuracy.

Authors:  Craig D C Bailey; Mariella De Biasi; Paul J Fletcher; Evelyn K Lambe
Journal:  J Neurosci       Date:  2010-07-07       Impact factor: 6.167

5.  Acetylcholine receptor (AChR) α5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (α4β2)₂α5 AChR function.

Authors:  Alexander Kuryatov; Wade Berrettini; Jon Lindstrom
Journal:  Mol Pharmacol       Date:  2010-09-29       Impact factor: 4.436

Review 6.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

7.  Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.

Authors:  Roger L Papke; Caryn Trocmé-Thibierge; Daniela Guendisch; Shehd Abdullah Abbas Al Rubaiy; Stephen A Bloom
Journal:  J Pharmacol Exp Ther       Date:  2011-02-01       Impact factor: 4.030

8.  Focus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.

Authors:  Xiomara A Pérez; Maryka Quik
Journal:  Mol Cell Pharmacol       Date:  2011

9.  Presynaptic GABAB autoreceptor regulation of nicotinic acetylcholine receptor mediated [(3)H]-GABA release from mouse synaptosomes.

Authors:  Tristan D McClure-Begley; Sharon R Grady; Michael J Marks; Allan C Collins; Jerry A Stitzel
Journal:  Biochem Pharmacol       Date:  2014-06-19       Impact factor: 5.858

10.  α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.

Authors:  Maryka Quik; Carla Campos; Tanuja Bordia; Jon-Paul Strachan; Jenny Zhang; J Michael McIntosh; Sharon Letchworth; Kristen Jordan
Journal:  Neuropharmacology       Date:  2013-04-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.